123 related articles for article (PubMed ID: 36260912)
21. Clinicopathological significance of matrix metalloproteinase 2 protein expression in patients with renal cell carcinoma: A case-control study and meta-analysis.
Liu Q; Zhang GW; Zhu CY; Wei JX; Tian X; Li Y; Li XD
Cancer Biomark; 2016; 16(2):281-9. PubMed ID: 26756619
[TBL] [Abstract][Full Text] [Related]
22. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
23. Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma.
Young JR; Coy H; Kim HJ; Douek M; Lo P; Pantuck AJ; Raman SS
AJR Am J Roentgenol; 2017 Apr; 208(4):812-819. PubMed ID: 28125273
[TBL] [Abstract][Full Text] [Related]
24. Rapid and sensitive detection of messenger RNA expression for molecular differential diagnosis of renal cell carcinoma.
Li G; Cuilleron M; Gentil-Perret A; Cottier M; Passebosc-Faure K; Lambert C; Genin C; Tostain J
Clin Cancer Res; 2003 Dec; 9(17):6441-6. PubMed ID: 14695146
[TBL] [Abstract][Full Text] [Related]
25. Chromophobe renal cell carcinoma: an immunohistochemical study of 21 Japanese cases.
Taki A; Nakatani Y; Misugi K; Yao M; Nagashima Y
Mod Pathol; 1999 Mar; 12(3):310-7. PubMed ID: 10102617
[TBL] [Abstract][Full Text] [Related]
26. Pretreatment differentiation of renal cell carcinoma subtypes by CT: the influence of different tumor enhancement measurement approaches.
Zokalj I; Marotti M; Kolarić B
Int Urol Nephrol; 2014 Jun; 46(6):1089-100. PubMed ID: 24381132
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma.
Mytsyk Y; Dosenko V; Borys Y; Kucher A; Gazdikova K; Busselberg D; Caprnda M; Kruzliak P; Farooqi AA; Lubov M
Int Urol Nephrol; 2018 May; 50(5):851-859. PubMed ID: 29549624
[TBL] [Abstract][Full Text] [Related]
28. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
[TBL] [Abstract][Full Text] [Related]
29. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
[TBL] [Abstract][Full Text] [Related]
30. Significance of nuclear grade and tumor size in Korean patients with chromophobe renal cell carcinoma: a comparison with conventional renal cell carcinoma.
Ku JH; Moon KC; Kwak C; Kim HH
Urol Oncol; 2011; 29(5):487-91. PubMed ID: 19767221
[TBL] [Abstract][Full Text] [Related]
31. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.
Morrissey JJ; Mellnick VM; Luo J; Siegel MJ; Figenshau RS; Bhayani S; Kharasch ED
JAMA Oncol; 2015 May; 1(2):204-12. PubMed ID: 26181025
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical study of c-KIT (CD117) expression in renal cell carcinoma.
Ahmed EA; Youssif ME
J Egypt Natl Canc Inst; 2009 Jun; 21(2):121-32. PubMed ID: 21057563
[TBL] [Abstract][Full Text] [Related]
34. Differentiation of renal cell carcinoma subtypes with different iodine quantification methods using single-phase contrast-enhanced dual-energy CT: areal vs. volumetric analyses.
Dai C; Cao Y; Jia Y; Ding Y; Sheng R; Zeng M; Zhou J
Abdom Radiol (NY); 2018 Mar; 43(3):672-678. PubMed ID: 28721478
[TBL] [Abstract][Full Text] [Related]
35. Diffusion kurtosis imaging features of renal cell carcinoma: a preliminary study.
Zhu Q; Xu Q; Dou W; Zhu W; Wu J; Chen W; Ye J
Br J Radiol; 2021 Jun; 94(1122):20201374. PubMed ID: 33989037
[TBL] [Abstract][Full Text] [Related]
36. Genetic subtyping of renal cell carcinoma by comparative genomic hybridization.
Junker K; Weirich G; Amin MB; Moravek P; Hindermann W; Schubert J
Recent Results Cancer Res; 2003; 162():169-75. PubMed ID: 12790331
[TBL] [Abstract][Full Text] [Related]
37. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
38. Radiology in the diagnosis and staging of renal cell carcinoma.
Zagoria RJ; Dyer RB; Wolfman NT; Hinn GC; Chen YM
Crit Rev Diagn Imaging; 1990; 31(1):81-115. PubMed ID: 2288659
[TBL] [Abstract][Full Text] [Related]
39. Distribution of subtypes of metastatic renal-cell carcinoma: correlating findings of fine-needle aspiration biopsy and surgical pathology.
Mai KT; Alhalouly T; Lamba M; Yazdi HM; Stinson WA
Diagn Cytopathol; 2003 Feb; 28(2):66-70. PubMed ID: 12561022
[TBL] [Abstract][Full Text] [Related]
40. Clear Cell Papillary Renal Cell Carcinoma: A Recent Entity With Distinct Imaging Patterns.
Tordjman M; Dbjay J; Chamouni A; Morini A; Timsit MO; Mejean A; Vasiliu V; Eiss D; Correas JM; Verkarre V; Helenon O
AJR Am J Roentgenol; 2020 Mar; 214(3):579-587. PubMed ID: 31770020
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
